This episode explores recent advances in the treatment of developmental and epileptic encephalopathies (DEEs), featuring expert insights from the recent European Epilepsy Congress (EEC 2026). Discussions cover the biology of Dravet syndrome, emerging disease-modifying approaches, including antisense oligonucleotides and gene therapy, and the Phase III GEMZ trial (NCT05064878) of fenfluramine in CDKL5 deficiency disorder. Experts also explore what defines disease modification in DEEs and how targeting underlying disease mechanisms could transform treatment approaches and improve long-term patient outcomes.

Featuring Nicola Specchio, MD, PhD, Bambino Gesù Children’s Hospital, Rome, Italy, and William Alves Martins, MD, Hospital São Lucas of PUCRS, Porto Alegre, Brazil.

This podcast is intended for healthcare professionals.